In a subsequent study, treatment of colorectal cancer cells with gilteritinib, which inhibits AXL as well as FLT3, caused AKT inhibition and consequent GSK-3β activation, which resulted in nuclear translocation of p65 and induction of PUMA as a mechanism of apoptosis induction, and GSK-3β knockdown suppressed gilteritinib-induced p65 phosphorylation and induction of PUMA (58). The gene discussed is AXL; the disease is colorectal cancer.